Morphiex Biotherapeutics | New publication highlights the importance of targeting thrombospondin-1 as well as “Don’t eat me”
491
post-template-default,single,single-post,postid-491,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-content-sidebar-responsive,qode-theme-ver-13.8,qode-theme-bridge,disabled_footer_top,disabled_footer_bottom

New publication highlights the importance of targeting thrombospondin-1 as well as “Don’t eat me”

Check out the new publication by our CEO, Dr. Anthony Schwartz which defines a new mechanism (Schlafen-11) through the CD47/thrombospondin-1 axis that is important for therapeutic resistance in cancer. Morphiex’s MBT-001 is the only drug that blocks “Don’t eat me” and thrombospondin-1 (TSP-1). This study was performed in collaboration with the National Cancer Institute (NCI/NIH) and The Wake Forest School of Medicine.

https://www.frontiersin.org/articles/10.3389/fonc.2019.00994/abstract



Location

240 Newbury Street, 2nd Floor
Boston, MA
info@morphiex.com

Social Media

Twitter Facebook LinkedIn